Nephronomics, a joint venture with Fresenius Medical Care, is a precision medicine company vertically integrating the world's most robust cardio-kidney-metabolic disease database of clinical and genomic data and ML models to develop targeted therapies against the underlying molecular mechanisms.
The genetic component of CKM disease remains significantly underappreciated in clinical practice. Through exclusive access to the My Reason® dataset with >35,000 patients, we're building the leading CKM disease model to discover new disease subtypes as well as both protective and disease-causing variants across the cardio-kidney-metabolic spectrum.
The Nephronomics Atlas enables the best powered and most comprehensive studies to discover protective and disease-causing variants in CKM disease, addressing the complex interrelationship between cardiovascular disease, kidney dysfunction, and metabolic disorders that often occur together.
Company Details
- Employees
- 2
- Founded
- -
- Address
- Greater Boston, Ma, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.nephronomics.com
- HQ
- Greater Boston, MA
Nephronomics Questions
Nephronomics's website is http://www.nephronomics.com
Nephronomics's LinkedIn profile is https://www.linkedin.com/company/nephronomics
Nephronomics has
2 employees.
View email and phone details for 2
employees at Nephronomics.
Nephronomics's industry is
Biotechnology Research
Nephronomics's top competitors are
212 Consulting Philippines,
Valuesnap,
Fresenius Medical Care,
Balboa Nephrology,
Baseline,
Frenova®,
My Reason,
Frenova, Llc,
Mechanica,
Seqone.
Nephronomics's categories are Biotechnology Research
Nephronomics's founding year is 2023
